The Adriacell Therapeutic Development Program Steering Committee is comprised of renowned international experts in the fields of drug development, biotechnology, oncology, pharmacology and molecular biology. The members are appointed by the Board of Directors and their main role is to advise Management on the progress of research and development activities
Maria Cristina Geroni, PhD
Maria C. Geroni holds a Masters Degree from the Medical and Biological School of the University of Milan. She has over 30 years' experience in the pharmaceutical Industry in oncology, preclinical and clinical R&D, and has held positions at Farmitalia-C.Erba and Pharmacia-Nerviano. She was Project Leader and Associate Director at Nerviano Medical Sciences. Maria C. Geroni has been involved in the development of new anthracyclines, camptothecins, taxanes, alkylating agents, natural products and cdk2 inhibitors as tumotherapeutic products. As a member of the Steering Committee she brings expertise in the field of preclinical research and development of oncology products.
Wolfgang Meyer, PhD
Wolfgang Meyer is a trained and board-certified pharmacist and pharmacologist with a PhD in Pharmaceutical Sciences and has more than 20 years´ of industry experience in drug development at Wyeth International, Fujisawa Group, Wilex, GPC Biotech and Oncobion. He was involved in the development of Bendamustine, FK506, MTX-HAS, FK866, Droloxifene, Leucovorine, Satraplatin, 1D09C3 (mAb), G250 (mAb), UK1, DRF 1042, CDK inhibitors and AK inhibitors. As a member of the Steering Committee, he brings expertise in the field of preclinical and clinical research with special emphasis on regulatory issues in oncology.